South Korea · Delayed Price · Currency is KRW Samsung Biologics Statistics
Total Valuation
KRX:207940 has a market cap or net worth of KRW 62.03 trillion. The enterprise value is 61.57 trillion.
| Market Cap | 62.03T |
| Enterprise Value | 61.57T |
Important Dates
The next estimated earnings date is Wednesday, July 22, 2026.
| Earnings Date | Jul 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:207940 has 46.29 million shares outstanding. The number of shares has decreased by -21.47% in one year.
| Current Share Class | 46.29M |
| Shares Outstanding | 46.29M |
| Shares Change (YoY) | -21.47% |
| Shares Change (QoQ) | -64.20% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 13.65% |
| Float | 11.84M |
Valuation Ratios
The trailing PE ratio is 51.24 and the forward PE ratio is 32.64. KRX:207940's PEG ratio is 0.59.
| PE Ratio | 51.24 |
| Forward PE | 32.64 |
| PS Ratio | 12.88 |
| PB Ratio | 7.83 |
| P/TBV Ratio | 7.90 |
| P/FCF Ratio | 41.92 |
| P/OCF Ratio | 26.59 |
| PEG Ratio | 0.59 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.94, with an EV/FCF ratio of 41.61.
| EV / Earnings | 32.78 |
| EV / Sales | 12.79 |
| EV / EBITDA | 21.94 |
| EV / EBIT | 27.47 |
| EV / FCF | 41.61 |
Financial Position
The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.70 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.43 |
| Debt / FCF | 0.81 |
| Interest Coverage | 76.74 |
Financial Efficiency
Return on equity (ROE) is 18.25% and return on invested capital (ROIC) is 23.35%.
| Return on Equity (ROE) | 18.25% |
| Return on Assets (ROA) | 9.43% |
| Return on Invested Capital (ROIC) | 23.35% |
| Return on Capital Employed (ROCE) | 23.98% |
| Weighted Average Cost of Capital (WACC) | 5.29% |
| Revenue Per Employee | 926.77M |
| Profits Per Employee | 361.51M |
| Employee Count | 5,047 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.84 |
Taxes
In the past 12 months, KRX:207940 has paid 567.88 billion in taxes.
| Income Tax | 567.88B |
| Effective Tax Rate | 24.48% |
Stock Price Statistics
The stock price has decreased by -15.59% in the last 52 weeks. The beta is 0.20, so KRX:207940's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -15.59% |
| 50-Day Moving Average | 1,491.00 |
| 200-Day Moving Average | 1,626.00 |
| Relative Strength Index (RSI) | 34.78 |
| Average Volume (20 Days) | 66,358 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:207940 had revenue of KRW 4.81 trillion and earned 1.88 trillion in profits. Earnings per share was 28,031.54.
| Revenue | 4.81T |
| Gross Profit | 2.64T |
| Operating Income | 2.22T |
| Pretax Income | 2.32T |
| Net Income | 1.88T |
| EBITDA | 2.78T |
| EBIT | 2.22T |
| Earnings Per Share (EPS) | 28,031.54 |
Balance Sheet
The company has 1.65 trillion in cash and 1.19 trillion in debt, with a net cash position of 458.47 billion or 9,904.01 per share.
| Cash & Cash Equivalents | 1.65T |
| Total Debt | 1.19T |
| Net Cash | 458.47B |
| Net Cash Per Share | 9,904.01 |
| Equity (Book Value) | 7.92T |
| Book Value Per Share | 171,153.01 |
| Working Capital | 1.92T |
Cash Flow
In the last 12 months, operating cash flow was 2.33 trillion and capital expenditures -852.77 billion, giving a free cash flow of 1.48 trillion.
| Operating Cash Flow | 2.33T |
| Capital Expenditures | -852.77B |
| Depreciation & Amortization | 564.80B |
| Net Borrowing | -244.49B |
| Free Cash Flow | 1.48T |
| FCF Per Share | 31,965.98 |
Margins
Gross margin is 54.86%, with operating and profit margins of 46.10% and 39.01%.
| Gross Margin | 54.86% |
| Operating Margin | 46.10% |
| Pretax Margin | 48.19% |
| Profit Margin | 39.01% |
| EBITDA Margin | 57.84% |
| EBIT Margin | 46.10% |
| FCF Margin | 30.73% |
Dividends & Yields
KRX:207940 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 21.47% |
| Shareholder Yield | 21.47% |
| Earnings Yield | 3.03% |
| FCF Yield | 2.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KRX:207940 is 2,104,879.79, which is 57.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2,104,879.79 |
| Price Target Difference | 57.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 14.77% |
| EPS Growth Forecast (3Y) | 25.35% |
Stock Splits
The last stock split was on October 30, 2025. It was a reverse split with a ratio of 0.6503913.
| Last Split Date | Oct 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.6503913 |
Scores
KRX:207940 has an Altman Z-Score of 13.26 and a Piotroski F-Score of 8.
| Altman Z-Score | 13.26 |
| Piotroski F-Score | 8 |